1Hou J,Yin YK, Xu D, et al. Telbivudine versus lamivudine inChinese patients with chronic hepatitis B: results at 1 year of arandomized, double-blind trial. Hepatology,2008,47 :447-454.
3Chan HL,Chen YC, Gane EJ,et al. Randomized clinical trial :efficacy and safety of telbivudine andlamivudine in treatment naivepatients with HBV-related decompensated cirrhosis. Journal ofViral Hepatitis, 2012, 19,732-743.
4Dienstag JL. The value and limitation of longterm nucleosideantiviral therapy in chronic hepatitis B. J Hepatol, 2005 , 42: 158-162.
5Hoeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk basedon the level of circulating hepatitis B viral load. Gastroenterology,2006,130: 678-686.
6Tacke F, 丁rautwein C. Hepatitis B goes globe : Telbivudine as anew treatment option. Hepatology,2008, 47: 1786-1787.
7Liaw YF, Sung JJ,Chow WC, et al. Lamivudine for patients withchronic hepatitis B and advanced liver Disease. N Engl J Med,2004,351 : 1521-1531.
8Chan HL,Chen YC,Gane EJ,et al. Randomized clinical trial :efficacy and safety of telbivudine and lamivudine in treatment-naivepatients with HBV-related decompensated cirrhosis. J ViralHepat, 2012,19: 732- 743.
